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PURPOSE: Test the hypothesis that symptomatic concussed athletes (CA) have a blunted 
increase in cerebral blood velocity during face cooling (FC) compared to healthy controls 
(HC). METHODS: Four CA (age: 202y) and five HC (age: 222y) completed 5 min resting 
baseline followed by 3 minutes of FC where a plastic bag filled with ice water (~0C) was placed 
on the forehead, eyes, and cheeks. Mean arterial pressure (MAP; photoplethysmography), middle 
cerebral artery blood velocity (MCAv; transcranial Doppler), and end-tidal partial pressure of 
CO2 (PETCO2; capnography) were recorded. Cerebral vascular resistance (CVR) was calculated 
as MAP/MCAv. Values are reported as a change from baseline to the third minute of 
FC. RESULTS: MAP (CA: 919 vs. HC: 919mmHg; P=0.46), MCAv (CA: 73.416.9 vs. HC: 
66.314.3cm/s; P=0.26), PETCO2 (CA: 442 vs. HC: 462mmHg; P=0.09), and CVR (CA: 
1.300.42 vs. HC: 1.430.34mmHg/cm/s; P=0.32) were not different at baseline. The change in 
MAP (CA: 197 vs. HC: 146mmHg; P=0.15) was not different between groups.  The change 
in MCAv was different between CA (4.95.8cm/s) and HC (-5.05.7cm/s; P=0.02).  The change 
in PETCO2 (CA: -11 vs. HC: -33mmHg; P=0.19) and CVR (CA: 0.200.19 vs. HC: 
0.370.24mmHg/cm/s; P=0.14) were not different between groups. CONCLUSION: HC 
experienced a reduction in MCAv during FC that might be attributed to the combined effects of 
the increase in CVR and reduction in PETCO2. CA experienced an increase in MCAv vs. 
HC that might be due to an attenuated rise in CVR.  These preliminary data indicate 
cerebrovascular dysfunction in symptomatic CA. Further research is warranted to determine the 
underlying cause of the increase in MCAv in CA during FC.   
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